Article information
Full text is only aviable in PDF
References
[1]
BR Celli.
MacNee W and committee members. Standards for the diagnosis and treatment of patients with COPD. A summary of the ATS-ERS position paper.
Eur Respir J, 23 (2004), pp. 932-946
[2]
DD Sin, SF Man.
Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality.
Proc Am Thorac Soc, 2 (2005), pp. 8-11
[3]
DD Sin, SF Man.
Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease.
Circulation, 107 (2003), pp. 1514-1519
[4]
SI Rennard.
Clinical approach to patients with chronic obstructive pulmonary disease and cardiovascular disease.
Proc Am Thorac Soc, 2 (2005), pp. 94-100
[5]
JA Barberá, G Peces-Barba, AG Agustí, JL Izquierdo, E Monsó, T Montemayor, et al.
Guía clínica para el diagnóstico y el tratamiento de la enfermedad pulmonar obstructiva crónica.
Arch Bronconeumol, 37 (2001), pp. 297-316
[6]
CJ Murray, AD López.
Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease study.
Lancet, 349 (1997), pp. 1498-1504
[7]
M Miravitlles, V Sobradillo, C Villasante, R Gabriel, JF Masa, CA Jiménez, et al.
Estudio epidemiológico de la EPOC en España (IBERPOC): reclutamiento y trabajo de campo.
Arch Bronconeumol, 35 (1999), pp. 152-158
[8]
J Escarrabill.
Costes sanitarios de la enfermedad pulmonar obstructiva crónica (EPOC).
Arch Bronconeumol, 39 (2003), pp. 435-436
[9]
JL Izquierdo Alonso, R Arroyo Espliguero.
EPOC y riesgo cardiovascular.
Arch Bronconeumol, 41 (2005), pp. 410-412
[10]
JB Soriano, JL Izquierdo Alonso.
EPOC en la vida y en la muerte.
Arch Bronconeumol, 42 (2006), pp. 421-422
[11]
JB Soriano, J Vestbo, NB Pride, V Kiri, C Maden, WC Maier.
Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice.
Eur Respir J, 20 (2002), pp. 819-825
[12]
PK MacCallum.
Markers of hemostasis and systemic inflammation in heart disease and atherosclerosis in smokers.
Proc Am Thorac Soc, 2 (2005), pp. 34-43
[13]
TW Meade, S Mellows, M Brozovic, GJ Miller, RR Chakrabarti, WR North, et al.
Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study.
Lancet, 2 (1986), pp. 533-537
[14]
J Danesh, R Collins, P Appleby, R Peto.
Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies.
JAMA, 279 (1998), pp. 1477-1482
[15]
RP Tracy, BM Psaty, E Macy, EG Bovill, M Cushman, ES Cornell, et al.
Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects.
Arterioscler Thromb Vasc Biol, 17 (1997), pp. 2167-2176
[16]
TA Pearson, GA Mensah, RW Alexander, JL Anderson, RO Cannon, M Criqui, et al.
Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.
Circulation, 107 (2003), pp. 499-511
[17]
AM Gotto Jr, JA Farmer.
Pleiotropic effects of statins: do they matter?.
Curr Opin Lipidol, 12 (2001), pp. 391-394
[18]
JK Liao.
Beyond lipid lowering: the role of statins in vascular protection.
Int J Cardiol, 86 (2002), pp. 5-18
[19]
GA Wellenius, PH Saldiva, JR Batalha, GG Krishna Murthy, BA Coull, RL Verrier, et al.
Electrocardiographic changes during exposure to residual oil fly ash (ROFA) particles in a rat model of myocardial infarction.
Toxicol Sci, 66 (2002), pp. 327-335
[20]
JA Wedzicha, TA Seemungal, PK MacCallum, EA Paul, GC Donaldson, A Bhowmik, et al.
Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels.
Thromb Haemost, 84 (2000), pp. 210-215
[21]
SF van Eeden, WC Tan, T Suwa, H Mukae, T Terashima, T Fujii, et al.
Cytokines involved in the systemic inflammatory response induced by exposure to particulate matter air pollutants (PM10).
Am J Respir Crit Care Med, 164 (2001), pp. 826-830
[22]
SF van Eeden, A Yeung, K Quinlam, JC Hogg.
Systemic response to ambient particulate matter: relevance to chronic obstructive pulmonary disease.
Proc Am Thorac Soc, 2 (2005), pp. 61-67
[23]
DB Hunninghake.
Cardiovascular disease in chronic obstructive pulmonary disease.
Proc Am Thorac Soc, 2 (2005), pp. 44-49
[24]
PM Ridker, N Rifai, L Rose, JE Buring, NR Cook.
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.
N Engl J Med, 347 (2002), pp. 1557-1565
[25]
Scandinavian Simvastatin Survival Study Group.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
Lancet, 344 (1994), pp. 1383-1389
[26]
J Shepherd, SM Cobbe, I Ford, CG Isles, AR Lorimer, PW MacFarlane, et al.
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
N Engl J Med, 333 (1995), pp. 1301-1307
[27]
GD Massaro, S Radaeva, LB Clerch, D Massaro.
Lung alveoli: endogenous programmed destruction and regeneration.
Am J Physiol Lung Cell Mol Physiol, 283 (2002), pp. 305-309
[28]
J Stein, H Fenigstein.
Anatomie pathologique de la maladie de famine.
Maladie de famine, pp. 21-27
[29]
M Calikoglu, G Sahin, A Unlu, C Ozturk, L Tamer, B Ercan, et al.
Leptin and TNF-alpha levels in patients with chronic obstructive pulmonary disease and their relationship to nutritional parameters.
Respiration, 71 (2004), pp. 45-50
[30]
I de Godoy, M Donahoe, WJ Calhoun, J Mancino, RM Rogers.
Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients.
Am J Respir Crit Care Med, 153 (1996), pp. 633-637
[31]
MA Higham, NB Pride, A Alikhan, NW Morrell.
Tumour necrosis factor-alpha gene promoter polymorphism in chronic obstructive pulmonary disease.
Eur Respir J, 15 (2000), pp. 281-284
[32]
A Bruno, P Chanez, G Chiappara, L Siena, S Giammanco, M Gjomarkaj, et al.
Does leptin play a cytokine-like role within the airways of COPD patients?.
Eur Respir J, 26 (2005), pp. 398-405
[33]
R Arroyo Espliguero, P Avanzas, S Jeffery, JC Kaski.
CD14 and toll-like receptor 4: a link between infection and acute coronary events?.
Heart, 90 (2004), pp. 983-988
[34]
JA Wedzicha, TA Seemungal, PK MacCallum, EA Paul, GC Donaldson, A Bhowmik, et al.
Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels.
Thromb Haemost, 84 (2000), pp. 210-215
[35]
M Roland, A Bhowmik, RJ Sapsford, TA Seemungal, DJ Jeffries, TD Warner, et al.
Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease.
Thorax, 56 (2001), pp. 30-35
[36]
A Aliverti, PT Macklem.
How and why exercise is impaired in COPD.
Respiration, 68 (2001), pp. 229-239
[37]
E Rappaport.
Cor pulmonale.
Textbook of respiratory medicine, pp. 1631-1648
[38]
DE O'Donnell, SM Revill, KA Webb.
Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 164 (2001), pp. 770-777
[39]
SR Salpeter, TM Ormiston, EE Salpeter, PJ Poole, CJ Cates.
Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis.
Respir Med, 97 (2003), pp. 1094-1101
[40]
H Yasue, M Yoshimura, H Sumida, K Kikuta, K Kugiyama, M Jougasaki, et al.
Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.
Circulation, 90 (1994), pp. 195-203
[41]
AJ de Bold, HB Borenstein, AT Veress, H Sonnenberg.
A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats.
Life Sci, 28 (1981), pp. 89-94
[42]
C Hall.
Essential biochemistry and physiology of (NT-pro)BNP.
Eur J Heart Fail, 6 (2004), pp. 257-260
[43]
E Bozkanat, E Tozkoparan, O Baysan, O Deniz, F Ciftci, M Yokusoglu.
The significance of elevated brain natriuretic peptide levels in chronic obstructive pulmonary disease.
J Int Med Res, 33 (2005), pp. 537-544
[44]
J Phua, TK Lim, KH Lee.
B-type natriuretic peptide: issues for the intensivist and pulmonologist.
Crit Care Med, 33 (2005), pp. 2094-2113
[45]
J Danesh, P Whincup, M Walker, L Lennon, A Thomson, P Appleby, et al.
Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis.
Circulation, 103 (2001), pp. 2323-2327
[46]
AJ Lee, GR Fowkes, GD Lowe, A Rumley.
Determinants of fibrin D-dimer in the Edinburgh artery study.
Arterioscler Thromb Vasc Biol, 15 (1995), pp. 1094-1097
[47]
G Fantuzzi.
Adipose tissue, adipokines, and inflammation.
J Allergy Clin Immunol, 115 (2005), pp. 911-919
[48]
S Kamath, GY Lip.
Fibrinogen: biochemistry, epidemiology and determinants.
Quart J Med, 96 (2003), pp. 711-729
[49]
I Behague, O Poirier, V Nicaud, A Evans, D Arveiler, G Luc, et al.
Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM study. Etude Cas-Temoins sur l'In-farctus du Myocarde.
Circulation, 93 (1996), pp. 440-449
[50]
JA Wedzicha, TA Seemungal, PK MacCallum, EA Paul, GC Donaldson, A Bhowmik, et al.
Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels.
Thromb Haemost, 84 (2000), pp. 210-215
[51]
M Rattazzi, M Puato, E Faggin, B Bertipaglia, A Zambon, P Pauletto.
C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders?.
J Hypertens, 21 (2003), pp. 1787-1803
[53]
PM Ridker, N Rifai, L Rose, JE Buring, NR Cook.
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.
N Engl J Med, 347 (2002), pp. 1557-1565
[54]
R Arroyo Espliguero, P Avanzas, J Cosin Sales, G Aldama, C Pizzi, JC Kaski.
C-reactive protein elevation and disease activity in patients with coronary artery disease.
Eur Heart J, 25 (2004), pp. 401-408
[55]
W Koenig, H Lowel, J Baumert, C Meisinger.
C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in Southern Germany.
Circulation, 109 (2004), pp. 1349-1353
[56]
SF Man, DD Sin.
Effects of corticosteroids on systemic inflammation in chronic obstructive pulmonary disease.
Proc Am Thorac Soc, 2 (2005), pp. 78-82
[57]
DD Sin, P Lacy, E York, SF Man.
Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 170 (2004), pp. 760-765
[58]
VM Keatings, PD Collins, DM Scott, PJ Barnes.
Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma.
Am J Respir Crit Care Med, 153 (1996), pp. 530-534
[59]
SD Aaron, JB Angel, M Lunau, K Wright, C Fex, N Le Saux, et al.
Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 163 (2001), pp. 349-355
[60]
RC Langen, AM Schols, MC Kelders, EF Wouters, YM Janssen-Heininger.
Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappa B.
FASEB J, 15 (2001), pp. 1169-1180
[61]
N Takabatake, H Nakamura, S Abe, S Inoue, T Hino, H Saito, et al.
The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 161 (2000), pp. 1179-1184
[62]
LT Nguyen, M Bedu, D Caillaud, B Beaufrere, G Beaujon, M Vasson, et al.
Increased resting energy expenditure is related to plasma TNF-alpha concentration in stable COPD patients.
Clin Nutr, 18 (1999), pp. 269-274
[63]
T Ishii, T Matsuse, S Teramoto, H Matsui, M Miyao, T Hosoi, et al.
Neither IL-1beta, IL-1 receptor antagonist, nor TNF-alpha polymorphisms are associated with susceptibility to COPD.
Respir Med, 94 (2000), pp. 847-851
[64]
JJ Atkinson, RM Senior.
Matrix metalloproteinase-9 in lung remodeling.
Am J Respir Cell Mol Biol, 28 (2003), pp. 12-24
[65]
AM Vignola, L Riccobono, A Mirabella, M Profita, P Chanez, V Bellia, et al.
Sputum metalloproteinase-9/tissue inhibitor of metallo-proteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis.
Am J Respir Crit Care Med, 158 (1998), pp. 1945-1950
[66]
B Avilés, J Belda, G Margarit, J Bellido-Casado, C Martínez-Bru, P Casan.
Marcadores de remodelado bronquial en el esputo inducido de fumadores sanos.
Arch Bronconeumol, 42 (2006), pp. 235-240
[67]
GK Sukhova, U Schonbeck, E Rabkin, FJ Schoen, AR Poole, RC Billinghurst, et al.
Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques.
Circulation, 99 (1999), pp. 2503-2509
[68]
E Antón Díaz, D Ruiz López, J Ancochea Bermúdez.
Herencia y ambiente en la EPOC.
Arch Bronconeumol, 43 (2007), pp. 10-17
[69]
H van der Vaart, DS Postma, W Timens, MN Hylkema, BW Willemse, HM Boezen, et al.
Acute effects of cigarette smoking on inflammation in healthy intermittent smokers.
Respir Res, 6 (2005), pp. 22-33
[70]
KA McCrea, JE Ensor, K Nall, ER Bleecker, JD Hasday.
Altered cytokine regulation in the lungs of cigarette smokers.
Am J Respir Crit Care Med, 150 (1994), pp. 696-703
[71]
S Lavi, A Prasad, EH Yang, V Mathew, RD Simari, CS Rihal, et al.
Smoking is associated with epicardial coronary endothelial dysfunction and elevated white blood cell count in patients with chest pain and early coronary artery disease.
Circulation, 115 (2007), pp. 2621-2627
[72]
JA Ambrose, RS Barua.
The pathophysiology of cigarette smoking and cardiovascular disease: an update.
J Am Coll Cardiol, 43 (2004), pp. 1731-1737
[73]
AM Wood, RA Stockley.
The genetics of chronic obstructive pulmonary, disease.
Respir Res, 7 (2006), pp. 130-144
[74]
TF Muller, M Vogl, MC Neumann, H Lange, M Grimm, MM Muller.
Noninvasive monitoring using serum amyloid A and serum neopterin in cardiac transplantation.
Clin Chim Acta, 276 (1998), pp. 63-74
[75]
ER Werner, A Bichler, G Daxenbichler, D Fuchs, LC Fuith, A Hausen, et al.
Determination of neopterin in serum and urine.
Clin Chem, 33 (1987), pp. 62-66
[76]
N Takabatake, M Sata, S Abe, S Inoue, H Saito, H Yuki, et al.
Impaired systemic cell-mediated immunity and increased susceptibility to acute respiratory tract infections in patients with COPD.
Respir Med, 99 (2005), pp. 485-492
[77]
P Avanzas, R Arroyo Espliguero, J Cosín-Sales, J Quiles, E Zouridakis, JC Kaski, et al.
Prognostic value of neopterin levels in treated patients with hypertension and chest pain but without obstructive coronary artery disease.
Am J Cardiol, 93 (2004), pp. 627-629
[78]
DT Johnston, M Gagos, N Raio, L Ragolia, D Shenouda, MA Davis-Lorton, et al.
Alterations in serum neopterin correlate with thrombolysis in myocardial infarction risk scores in acute coronary syndromes.
Coron Artery Dis, 17 (2006), pp. 511-516
[79]
M Kolb, PJ Margetts, DC Anthony, F Pitossi, J Gauldie.
Transient expression of IL-1 beta induces acute lung injury and chronic repair leading to pulmonary fibrosis.
J Clin Invest, 107 (2001), pp. 1529-1536
[80]
G Peces-Barba Romero.
Etiopatogenia del atrapamiento aéreo en la EPOC.
Arch Bronconeumol, 41 (2005), pp. 9-17
[81]
SA Kharitonov, P Barnes.
Exhaled markers of pulmonary disease.
Am J Crit Care Med, 163 (2001), pp. 1693-1722
[82]
JL Izquierdo, C Almonacid, T Parra, J Pérez.
Inflamación pulmonar y sistémica en dos fenotipos de EPOC.
Arch Bronconeumol, 42 (2006), pp. 332-337
[83]
P Jakobsson, L Jorfeldt, A Brundin.
Skeletal muscle metabolites and fiber types in patients with advanced chronic obstructive pulmonary disease (COPD), with and without chronic respiratory failure.
Eur Respir J, 3 (1990), pp. 192-196
[84]
PD Thompson, D Buchner, IL Piña, GJ Balady, MA Williams, BH Macus, et al.
Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease. A statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity).
Circulation, 107 (2003), pp. 3109-3116
[85]
M Montes de Oca, SH Torres, Y González, E Romero, N Hernández, C Tálamo.
Cambios en la tolerancia al ejercicio, calidad de vida relacionada con la salud y características de los músculos periféricos después de 6 semanas de entrenamiento en pacientes con EPOC.
[86]
L Puente Maestu, T Tena, C Trascasa, J Pérez Parra, R Godoy, MJ García, et al.
Training improves muscle oxidative capacity and oxygenation recovery kinetics in patients with chronic obstructive pulmonary disease.
Eur J Appl Physiol, 88 (2003), pp. 580-587
Copyright © 2008. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
